Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma

INTRODUCTION: Hepatocellular carcinoma (HCC) accounts for 80% of all liver cancers and is the 2nd leading cause of cancer-related death in Taiwan. Various factors, including rapid cell growth, a high recurrence rate and drug resistance, make HCC difficult to cure. Moreover, the survival rate of adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chao-Jen, Tsai, Hung-Wen, Chen, Yi-Li, Wang, Chun-I, Lin, Yang-Hsiang, Chu, Pei-Ming, Chi, Hsiang-Cheng, Huang, Yi-Ching, Chen, Cheng-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896975/
https://www.ncbi.nlm.nih.gov/pubmed/36741246
http://dx.doi.org/10.2147/JHC.S385238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896975/
https://www.ncbi.nlm.nih.gov/pubmed/36741246
http://dx.doi.org/10.2147/JHC.S385238

Ejemplares similares